Semaglutide is an oral glucagon-like peptide receptor agonist approved in 2019 by the U.S. Food and Drug Administration. It is marketed under the brand name Rybelsus and was approved to be used in conjunction with lifestyle modifications to treat individuals with type 2 diabetes. It is the first in its drug class to be administered in a once-daily oral form. Through its actions on glucose control and body weight, this once-daily oral medication could contribute to better glycemic control and healthier lives for many women with type 2 diabetes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.nwh.2020.07.005 | DOI Listing |
Publication Analysis
Top Keywords
once-daily oral
12
type diabetes
12
oral medication
8
semaglutide once-daily
4
oral
4
medication treat
4
treat type
4
diabetes semaglutide
4
semaglutide oral
4
oral glucagon-like
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!